Background The incidence of brain metastases (BM) in melanoma patients is common and
associated with poor prognosis. MAP-kinase inhibitors and immunologic checkpoint …

Background Melanoma brain metastasis is associated with an extremely poor prognosis,
with a median overall survival of 4–5 months. Since 2011, the overall survival of patients …

Background The impact of the order of treatment with checkpoint inhibitors or BRAF/MEK
inhibitors on the development of brain metastases in patients with metastatic unresectable …

The successes of checkpoint blockade immunotherapy (CBI) and BRAFV600-targeted
therapy trials have generated substantial promise for revolutionizing the management of …

Simple Summary Cutaneous melanoma is highly prone to metastasize to the brain, with a
historically poor overall survival of only 4–5 months. Over the past decade, novel drugs such …

Melanoma brain metastases (MBM) are common and associated with a particularly poor
prognosis; they directly cause death in 60–70% of melanoma patients. In the past, systemic …

BACKGROUND The development of brain metastases is common for systemic treatment
failure in patients with melanoma and has been associated with a poor prognosis. Recent …

Metastatic disease to the brain is a frequent manifestation of melanoma and is associated
with a very poor outcome. Systemic therapy with cytotoxic chemotherapy provide only a …

Background Historically, the prognosis for patients who have melanoma brain metastasis
(MBM) has been dismal. However, breakthroughs in targeted and immunotherapies have …

Background Recent therapeutic strategies, particularly MAP kinase pathway inhibitors
(BRAF, MEK) and immune checkpoint blockers (CTLA-4, PD-1), have been put on the test …